🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Jingyuan Wang

University of Pittsburgh

ORCID: 0000-0003-1180-5050
Materials ScienceMedicineEngineering

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 6 papers. Top paper: Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study..

20 citations

Peipei Lu, Wen Xie, Jingyuan Wang

26 citations

Ye Feng, Brian Liu, Wen Xie, Jingyuan Wang

5 citations

Ziteng Zhang, Jibin Guan, Hung‐Chun Tung, Jiaxuan Xie, Haozhe Huang +8 more

18 citations

Jong‐Won Kim, Junjie Zhu, Sihan Li, Jiong Yan, Qing Liu +21 more

2 citations

Gregory Young, Min Zhang, Sonia R. Salvatore, Fu‐Ying Qin, Xinran Cai +13 more